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Abstract
Objective: People with velo-cardio-facial syndrome or 22q11 deletion syndrome (22q11DS) have behavioral, cognitive and
psychiatric problems. Approximately 30% of affected individuals develop schizophrenia-like psychosis. Glutamate
dysfunction is thought to play a crucial role in schizophrenia. However, it is unknown if and how the glutamate system
is altered in 22q11DS. People with 22q11DS are vulnerable for haploinsufficiency of PRODH, a gene that codes for an
enzyme converting proline into glutamate. Therefore, it can be hypothesized that glutamatergic abnormalities may be
present in 22q11DS.
Method: We employed proton magnetic resonance spectroscopy (1H-MRS) to quantify glutamate and other
neurometabolites in the dorsolateral prefrontal cortex (DLPFC) and hippocampus of 22 adults with 22q11DS (22q11DS
SCZ+) and without (22q11DS SCZ2) schizophrenia and 23 age-matched healthy controls. Also, plasma proline levels were
determined in the 22q11DS group.
Results: We found significantly increased concentrations of glutamate and myo-inositol in the hippocampal region of
22q11DS SCZ+ compared to 22q11DS SCZ2. There were no significant differences in levels of plasma proline between
22q11DS SCZ+ and 22q11DS SCZ2. There was no relationship between plasma proline and cerebral glutamate in 22q11DS.
Conclusion: This is the first in vivo 1H-MRS study in 22q11DS. Our results suggest vulnerability of the hippocampus in the
psychopathology of 22q11DS SCZ+. Altered hippocampal glutamate and myo-inositol metabolism may partially explain the
psychotic symptoms and cognitive impairments seen in this group of patients.
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Introduction
Velo-cadio-facial-syndrome or 22q11 deletion syndrome
(22q11DS) is a genetic syndrome caused by a deletion on
chromosome 22 which is accompanied by several somatic,
behavioral, cognitive and psychiatric problems, and structural
and functional brain abnormalities [1]. The estimated prevalence
of 22q11DS in the general population is 1 in 5950 births [2].
Adults with 22q11DS face a 25 times higher risk of developing
schizophrenia than the general population [3] and in people with
schizophrenia an increased frequency of 22q11 deletions has been
reported [4,5]. Hence, a 22q11 deletion is among the highest risk
factors for the development of schizophrenia.
People with 22q11DS are vulnerable to haploinsufficiency of
approximately 30 genes located on the deleted region of
chromosome 22q11, including the proline dehydrogenase gene
(PRODH) [6]. This gene, which encodes for the PRODH enzyme
also called proline oxidase (POX), is involved in converting proline
to glutamate [7]. Dysfunction or genetic variations of the PRODH
gene, and consequent hyperprolinemia, have been associated with
susceptibility to schizophrenia and with learning disabilities [8–
13]. In fact, proline has been shown to function as modulator of
glutamate neurotransmission through NMDA receptors [14,15]
and dysregulation of the glutamatergic system has been widely
implicated in schizophrenia.
The involvement of glutamate in schizophrenia is particularly
related to NMDA receptor hypofunction. Evidence for the role of
NMDA receptor hypofunction in schizophrenia comes from
pharmacological studies of phencyclidine (PCP) and ketamine.
These NMDA receptor antagonists have shown to produce
schizophrenia-like behaviors in rodents [16]; to induce positive
and negative symptoms in healthy humans [17]; and to aggravate
psychotic symptoms in patients with schizophrenia [18]. Gluta-
mate also plays a role in synaptic plasticity via NMDA receptors
mediating higher cognitive functions such as learning and
memory. NMDA receptor dysfunction has also been implicated
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in the cognitive deficits of schizophrenia [19]. In these people,
agents that enhance NMDA receptor activity have shown to
improve negative symptoms and to facilitate memory consolida-
tion [20].
The brain areas associated with NMDA receptor hypofunction
in schizophrenia include the prefrontal cortex and hippocampus
[21–24]. The relationship between NMDA receptor hypofunction
and glutamate release is not fully understood. NMDA hypofunc-
tion in schizophrenia could be related to insufficient or excessive
glutamate release which may also differ between brain regions
[25]. Increased glutamate exposure and its duration could explain
the psychotoxic effects in schizophrenia.
Proton Magnetic Resonance Spectroscopy (1H-MRS) is a
feasible method for in vivo quantification of glutamate concentra-
tion and other brain metabolites that, if altered, may reflect
abnormal neuro-developmental features [26]. In schizophrenia an
increasing number of 1H-MRS studies have been conducted.
Although inconclusive, 1H-MRS findings also suggest abnormal
glutamatergic neurotransmission [27–29].
To date, the glutamatergic system in 22q11DS has not been
investigated. People with 22q11DS have an increased prevalence
of schizophrenia and similar neuroanatomical abnormalities.
Hence, in this study we employed 1H-MRS to measure glutamate
in the dorsolateral prefrontal cortex and hippocampus in 22q11DS
patients with (22q11DS SCZ+) and without schizophrenia
(22q11DS SCZ2). We hypothesized altered glutamate concen-
trations in individuals with 22q11DS SCZ+ compared to healthy
individuals and, in 22q11DS SCZ+ compared to 22q11DS SCZ2.
Besides glutamate, we also analyzed other neurometabolites from
1H-MRS spectra including N-acetylaspartate, choline, myo-
inositol and creatine which reflect the status of neuronal
functioning and glial cells, possibly disturbed in 22q11DS.
Furthermore, we assessed levels of plasma proline and plasma
glutamine in the 22q11DS group. Increased proline has been
reported in 22q11DS patients [30]. In children with 22q11DS
there was a relationship between increased plasma proline and
decreased brain function [31]. High levels of proline in 22q11DS,
consequence of POX deficiency, may be related to glutamate
dysfunction particularly in 22q11DS SCZ+. Hence, we expected
that plasma proline will be increased in 22q11DS SCZ+ and that it
will correlate with glutamate concentrations in the brain.
Materials and Methods
Subjects
We included 22 adults with 22q11DS (mean 6 SD) (22q11DS
SCZ+ n=12, age 29.2568.24; 22q11DS SCZ2 n=10, age
28.5068.47) and 23 healthy controls (HC, age 31.2269.58).
Individuals with 22q11DS were recruited through the Dutch
22q11DS family association and through the departments of three
Dutch Clinical Genetics centers. Healthy volunteers were
recruited by local advertisement. The study was conducted at
the Department of Psychiatry, Academic Medical Centre
Amsterdam (AMC), The Netherlands and was approved by the
Medical Ethics Testing Committee/AMC. All participants were
capable of giving written informed consent and did so, after
receiving full information on the study.
All individuals with 22q11DS were assessed by an experienced
psychiatrist and a physician for people with an intellectual
disabilities using available information from medical records and
a semi-structured psychiatric interview. All diagnoses reported are
DSM-IV diagnoses (American Psychiatric Association, 1994). The
22q11DS group was subdivided into 2 groups: those who were
fulfilling DSM-IV criteria for schizophrenia (22q11DS SCZ+) all
taking antipsychotic medication and having duration of illness .1
year (dose ranges and haloperidol equivalents [32] are displayed in
Table 1) and those who did not have a past or current psychiatric
history and had never taken antipsychotic or stimulant medication
(22q11DS SCZ2).
In addition, the Positive and Negative Symptom Scale (PANSS)
[33] was used to assess positive, negative and general psychopa-
thology in the 22q11DS SCZ+ group. The PANSS includes 30
items, subdivided in three categories: positive symptoms, negative
symptoms and general psychopathology. A patient who rates
‘‘absent’’ (or 1) on all items would receive a total score of 30 and a
subject who rates ‘‘extreme’’ (or 7) on all 30 items would receive a
total score of 210. All patients underwent a formalized clinical
interview of 35–40 minutes and the questions were in regard to
the last two weeks.
For assessment of intelligence quotient (IQ) we used the
shortened Dutch version of the Wechsler Adult Intelligence Scale
(WAIS-III–NL) consisting of 5 subtests: vocabulary, comprehen-
sion, similarities (verbal IQ), block design, and object assembly
(performance IQ) [34,35].
All healthy volunteers were seen by a physician. They were
included in the study after screening for psychiatric disorders and
medical conditions affecting the brain. None of the participants
had a history of substance or alcohol abuse. Urine drug screening
(cocaine, tetrahydrocannabinol, opiates, amphetamines, benzodi-
azepines) was performed at study day and was negative in all
subjects. Healthy participants were not using any medication at
the time of testing.
1H-MR spectroscopy acquisition
1H-MRS data acquisition took place at the Department of
Radiology (Academic Medical Centre Amsterdam, The Nether-
lands) using a 3 Tesla Intera MRI system (Philips, Best, The
Netherlands) equipped with a 6 channel sense head coil. For
estimation of metabolite concentrations, two single 8 ml voxels of
interest positioned in the left dorsolateral prefrontal cortex
(DLPFC) (26262 cm) and left hippocampus (26262 cm) were
obtained for each subject (Figure 1). More specifically, the
hippocampal voxel included areas of the hippocampus, para-
hippocampal gyrus, fusiform gyrus and collateral sulcus. Iterative
first order shimming was performed and water suppressed spectra
was acquired using a point-resolved spatially localized spectrosco-
py sequence (PRESS, TE 36 ms, TR 2000 ms, 128 averages).
Table 1. Medication and dosage taken by 22q11DS patients
with schizophrenia.
Drugs Dosis (mg/d)
Haloperidol
equivalent (mg/d)a N
Aripiprazole 5–15 1–7.5 3
Atomoxetineb 80 1
Clozapine 200–300 4–6 2
Methylphenidatec 36 1
Olanzapine 5 2.5 1
Quetiapine 50 0.5 2
Risperidone 3–4 5–6.7 2
Zuclopentixol 6 1.2 1
aHaloperidol equivalents derived from kane et al (2003).
bOne patient took an antipsychotic and a selective norepinephrine inhibitor.
cOne patient took an antipsychotic and a psychostimulant drug.
doi:10.1371/journal.pone.0021685.t001
1H-MRS in 22q11DS
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For anatomical localization transversal high-resolution structur-
al T1-weighted volumetric images, with full head coverage, using
130 contiguous slices (1.2 mm thick, with 0.8960.89 mm in-plane
resolution) and a TR/TE of 9.8/4.5 milliseconds (flip angle 80,
FOV 224 cm) were obtained.
1H-MRS spectra were analyzed using the Linear Combination
of Model spectra (LCModel) commercial spectral-fitting package
[36]. LCModel used a library of reference spectra in a basis set
recorded specifically for the scanner and calibrated using the tissue
water signal as an internal standard. The spectra were analyzed
with a range of 3.8 ppm to 0.2 ppm (Figure 2). From the
metabolites included in the LCModel basis set, we analyzed
absolute levels of creatine plus phosphocreatine (Cr), glyceropho-
sphocholine plus phosphocholine (choline), myo-inositol, N-acetylas-
partate (NAA), NAA plus N-acetylaspartylglutamate (NAAG),
glutamine and glutamate.
In addition, we analyzed the combination of glutamate plus
glutamine (Glx). Glutamate and glutamine are closely related
amino acids involved in intermediary metabolism, protein
synthesis and neurotransmission. Metabolite concentrations are
expressed in millimoles per liter.
Data were excluded from analysis if the voxel coordinates were
not or incorrectly recorded. Spectral width (full width at half
maximum, FWHM) was always lower than 0.1 p.p.m. and signal
to noise ratio (SNR) greater than 11 as estimated by LCModel.
Cramer-Rao minimum variance bounds (SD) was lower than 50%
for glutamine and lower than 15% for the other metabolites.
Plasma amino-acid analyses
Plasma proline and plasma glutamine concentrations of the
22q11DS group were assessed by automated ion exchange
chromatography with post-column ninhydrin derivatization.
Plasma amino-acid analyses were performed on a JEOL
AminoTac (JEOL AminoTac JLC-500/V, Tokyo, Japan) follow-
ing a morning blood draw.
Statistical analyses
We used non-parametric Kruskal-Wallis H test to compare
metabolite concentrations, age and IQ between the 3 groups (HC,
22q11DS SCZ+ and 22q11DS SCZ2) because the assumption of
normal distribution was not met. Following, Post Hoc analyses
were conducted with Mann-Whitney U tests. Correlation analyses
were conducted with Spearman’s rho test. Results are reported as
significant when P#0.05 (2-tailed). Statistical analyses were
performed with SPSS, release 16.0.2 for Windows (SPSS Inc.,
Chicago, IL, USA. 2008).
Results
Demographics
Patients and healthy controls did not differ with regard to sex
(HC 12m/11f, 22q11DS SCZ+ 8m/4f, 22q11DS SCZ2 4m/6f
P=0.45) and age (HC 31.2269.51, 22q11DS SCZ+ age
29.2568.24, 22q11DS SCZ2 28.5068.47; P=0.89).
Patients had a lower total IQ than healthy controls (HC
111.88614.82, 22q11DS SCZ+ 69.67613.82, 22q11DS SCZ2
81.8667.01; P,0.001). Also verbal IQ (HC 112.88615.96,
22q11DS SCZ+ 75.00611.24, 22q11DS SCZ2 85.8669.33;
P=0.001) and performance IQ (HC 109.38619.91, 22q11DS
SCZ+ 67.89616.60, 22q11DS SCZ2 79.43610.53; P=0.002)
were significantly different between the groups. Post hoc analysis
showed that HC compared to 22q11DS SCZ+ differed signifi-
cantly for total IQ P=0.001, verbal IQ P=0.001 and perfor-
mance IQ P=0.001. HC compared to 22q11DS SCZ2 differed
significantly for total IQ P=0.004, verbal IQ= P=0.005 and
performance IQ P=0.01. 22q11DS SCZ+ compared to 22q11DS
SCZ2 differed significantly for total IQ P=0.02 and verbal IQ
P=0.02 but not performance IQ P=0.17.
For the 22q11DS SCZ+ group, the mean score on the general
psychopathology PANSS subscale was 30.69611.94, the negative
subscale was 17.5568.21 and the positive subscale was 10.6963.81.
The mean of total PANSS score was 58.95621.85.
Metabolites
Metabolite concentrations for the DLPFC and hippocampal
region are displayed in Table 2. Kruskal-Wallis H test showed no
significant group differences in any of the metabolite concentra-
tions in the DLPFC. In the hippocampal region, significant group
differences were found in concentrations of glutamate (P=0.03)
Glx (P=0.03) and myo-inositol (P=0.03). Post Hoc analysis
indicated that these metabolite concentrations were significantly
higher in 22q11DS SCZ+ compared to 22q11DS SCZ2 patients
(glutamate P=0.02; Glx P=0.03 and myo-inositol P=0.01).
Hippocampal Glx was higher in 22q11DS SCZ+ compared to HC
(P=0.02). In the DLPFC there was a significant positive
correlation between glutamine concentration and antipsychotic
dosage (n = 10 r=0.64 P=0.05) and a trend towards a positive
correlation between Glx and antipsychotic dosage (n = 10 r=0.59
P=0.07). There were no significant correlations between hippo-
campal metabolites and antipsychotic dosage.
Plasma Proline and Plasma Glutamine
For the whole 22q11DS group, the mean6SD for plasma
proline was n= 13, 3546128.88 mmol/l and for plasma glutamine
n= 8, 540.62668.14 mmol/l. The correlation between these
variables was not significant (n = 8 r=0.26 P=0.53). The normal
laboratory range for plasma proline was 77–343 mmol/l and for
plasma glutamine 344–743 mmol/l.
There were no significant differences between 22q11DS SCZ2
and 22q11DS SCZ+ for plasma proline (22q11DS SCZ2 n=8,
376.376145.64 mmol/l, 22q11DS SCZ+ n=5, 318.206100.56
mmol/l; P=0.56) or plasma glutamine (22q11DS SCZ2 n=4,
555.25679.47 mmol/l, 22q11DS SCZ+ n=5, 540.80663.70 mmol/
Figure 1. Sargittal T1-weighted magnetic resonance image of
the brain showing voxel (26262 cm) placement for proton
magnetic resonance spectroscopy (1H-MRS) in the left dorso-
lateral prefrontal cortex and left hippocampus.
doi:10.1371/journal.pone.0021685.g001
1H-MRS in 22q11DS
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Figure 2. Sample of a 1H-MRS spectrum from hippocampus of a patient with 22q11DS as fit by LCModel.
doi:10.1371/journal.pone.0021685.g002
Table 2. Metabolites concentrations (mean/SD) in the DLPFC and hippocampal region in healthy controls and 22q11DS with and
without psychosis.
DLPFC HC SCZ2 SCZ+ HIP HC SCZ2 SCZ+
n= 23 7 11 n= 16 7 9
Glu 6.44/1.35 6.35/1.02 6.39/1.32 Glua 6.26/0.65 5.71/0.94 6.99/1.04
Gln 2.86/0.94 2.66/0.83 3.25/1.37 Gln 3.03/0.83 3.12/0.58 3.88/1.67
Glx 9.17/2.06 8.64/1.29 9.65/2.28 Glxab 9.29/0.94 8.83/1.11 10.87/1.66
mI 3.51/0.54 3.35/0.50 3.46/0.83 mIa 3.87/0.63 3.47/0.40 4.43/0.76
NAA 6.07/0.79 5.38/0.63 5.89/0.82 NAA 5.03/0.57 4.63/0.85 5.25/1.18
NAA+NAAG 6.68/0.82 5.96/0.92 6.41/1.11 NAA+NAAG 5.64/0.75 5.44/0.72 6.06/1.09
Cho 1.38/0.16 1.34/0.22 1.43/0.20 Cho 1.58/0.18 1.54/0.17 1.71/0.25
Cr 5.06/0.60 4.80/0.38 5.06/0.60 Cr 4.96/0.54 4.70/0.64 5.25/0.86
HC: Healthy controls SCZ2: 22q11DS without psychosis SCZ+: 22q11DS with psychosis.
Glu: glutamate Gln: glutamine Glx: Glu+Gln NAA: N-acetylaspartate.
NAA+NAAG: NAA+N-acetylaspartylglutamate mI: myo-inositol Cr: creatine Cho: choline.
Metabolite concentrations are expressed in millimoles per liter.
aP,0.05 for SCZ2 vs. SCZ+.
bP= 0.05 for HC vs. SCZ+.
doi:10.1371/journal.pone.0021685.t002
1H-MRS in 22q11DS
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l; P=0.78). There was no significant correlation between plasma
proline and plasma glutamine in any of the two 22q11DS groups.
The correlation between DLPFC glutamate and plasma proline
for the whole 22q11DS group was not significant (n = 11 r=0.26
P=0.43). Also, there was no significant correlation between
proline and DLPFC glutamate for the 22q11DS SCZ2 (n = 5
r=0.30 P=0.62) and 22q11DS SCZ+ group (n= 6 r=0.37
P=0.47).
The correlation between hippocampal glutamate and plasma
proline for the whole 22q11DS group was not significant (n = 10
r=0.21 P=0.56). There was no significant correlation between
proline and hippocampal glutamate for the 22q11DS SCZ2
(n = 6 r=0.03 P=0.96) and 22q11DS SCZ+ group (n= 4
r=0.40 P=0.80).
Discussion
In this first in vivo 1H-MRS study in 22q11DS we measured
metabolite concentrations of the DLPFC and hippocampal region
in adults with and without schizophrenia and in healthy controls.
Our main findings are increased hippocampal glutamate and myo-
inositol concentrations in 22q11DS SCZ+ compared to 22q11DS
SCZ2. Metabolites of the DLPFC did not differ significantly
across the groups.
1H-MRS studies of the hippocampus in schizophrenia have
shown ambivalent results concerning glutamate; some studies
reported no alterations of glutamate concentrations in subjects
experiencing prodromal symptoms of schizophrenia [37] or in
chronic schizophrenia [38,39]. Other studies reported increased
hippocampal glutamate in patients with schizophrenia [40] or a
tendency towards increased glutamate in a group of medicated
first episode patients [41].
In the present 1H-MRS study we found increased concentration
of glutamate and Glx in the hippocampal region of 22q11DS
SCZ+ compared to 22q11DS SCZ2. Also, hippocampal Glx was
increased in 22q11DS SCZ+ compared to healthy controls.
Excessive release of glutamate and consequent overstimulation of
postsynaptic receptors might have an influence on the cognitive
and psychotic symptoms associated with the NMDA hypofunction
in schizophrenia [25]. In line with this observation and in
agreement with previous research in schizophrenia, our finding of
increased hippocampal glutamate in 22q11DS SCZ+ suggests that
glutamate disturbance may be underlying psychotic symptoms in
22q11DS SCZ+. Moreover, the 22q11DS SCZ+ had overall lower
IQ than 22q11DS SCZ2. Increased hippocampal glutamate
could also explain the cognitive impairment in 22q11DS SCZ+
since this brain area is involved in learning and memory functions.
Although speculative, increased hippocampal glutamate in
22q11DS SCZ+ might also indicate NMDA receptor hypofunc-
tion in this group.
Glutamate neurotransmission may in part be influenced by
proline. Increased concentrations of proline associated with
hyperprolinemia type II (proline levels 10–15 fold above normal)
have been shown to potentiate glutamate transmission in
hippocampus and cerebral cortex [15,42]. Hyperprolinemia of
the type I has been observed in patients with 22q11DS (plasma
proline levels with a range of 3–10 fold above normal) which
results from inherited deficiency of POX enzyme [12,30]. In the
present study half of the 22q11DS patients had elevated proline
levels. Contrary to our expectation, we found similar proline levels
in 22q11DS SCZ+ and 22q11DS SCZ2. Increased proline levels
may depend on genetic variation of the PRODH allele [8] or on
interaction with other genes. For instance, a study of hyperpro-
linemia in 22q11DS showed an association between hyperprolin-
emia and psychosis in 22q11DS patients only when Met, the low
activity allele of the COMT gene, was taken into account [12]. We
found no correlation between plasma proline, plasma glutamine
and cerebral glutamate concentrations in the whole 22q11DS
group or in 22q11DS SCZ2 vs. 22q11DS SCZ+. Thus, although
we found increased hippocampal glutamate concentrations in
22q11DS SCZ+, its underlying mechanisms remain unclear.
In addition to increased hippocampal glutamate, we found higher
concentrations of myo-inositol in 22q11DS SCZ+ compared to
22q11DS SCZ2. Increased concentrations of myo-inositol have
previously been reported in mild cognitive impairment and
Alzheimer disease [43,44]. Also in Down syndrome increased
hippocampal myo-inositol has been associated with reduced
cognitive ability [45]. Changes in myo-inositol levels may reflect
abnormalities in membrane metabolism, in intracellular signaling
mechanisms, neuronal development and survival [46]. Hence,
increased myo-inositol may explain part of the hippocampal brain
abnormalities and learning disabilities seen in 22q11DS SCZ+.
The finding of increased glutamate and myo-inositol may be
tightly related to each other in the psychopathology in 22q11DS
SCZ+. Myo-inositol is primarily found in astrocytes [47] which
interact with neurons and play a critical role in the synthesis of
glutamate [48,49]. Elevated concentration of myo-inositol may
indicate increased number or increased metabolic activity of
astrocytes. Astrocyte dsysregulation in turn may trigger increased
glutamate uptake and glutamate-glutamine cycling conversion.
This could reflect altered glutamatergic neurotransmission in this
genetic predisposed group, which combined with environmental
interaction may increase the vulnerability for development of
schizophrenia.
We found no significant variation in neurometabolites concen-
tration between the whole 22q11DS patient group and the healthy
control group. This might be explained by group differences in the
proportion of gray matter/white matter within the DLPFC and
hippocampal voxels. Also, we found no evidence for altered
glutamate in the DLPFC of 22q11DS patients (22q11DS SCZ+ vs.
22q11DS SCZ2) vs. healthy controls. In patients with chronic
schizophrenia, 1H-MRS studies of the frontal cortex have shown
increased [40,50,51] and reduced glutamate concentrations
[29,39,52,53]. Perhaps, brain dysfunction associated with psycho-
sis in 22q11DS involves specific regions of the temporal lobe
[54,55]. Furthermore, it is also possible that abnormalities in
glutamatergic function in this brain region may exist at the level
of NMDA receptor or in second messenger signaling without
alterations in glutamate concentration.
An interesting observation is that most of the metabolite
contents are in the order of 22q11DS SCZ2,HC,22q11DS
SCZ+. We are not aware of an existing explanation for this
relation in the literature. However, we hypothesize that prior to
the development of schizophrenia patients with 22q11DS in
general may have decreased neuronal metabolism as has been
observed for glutamate in individuals with increased vulnerability
to schizophrenia (at risk mental state - ARMS) [56,57]. On the
other hand, an instable neuronal metabolism may predispose a
subgroup of 22q11DS patients to psychotic decompensation.
Another possibility is that higher metabolites in the 22q11DS
patients are the result of the transition to psychosis instead of the
cause. This would mean that high metabolic rates in 22q11DS are
state- instead of trait-related. Due to the cross-sectional design of
our study we are unable to confirm this hypothesis. Longitudinal
research in 22q11DS patients before and after transition to
psychosis is therefore warranted.
The strengths of this study include the evaluation of neuronal
integrity in 22q11DS according to psychiatric status of 22q11DS
1H-MRS in 22q11DS
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SCZ2 and 22q11DS SCZ+ and in comparison to age matched
healthy controls. Also, all MRS spectra were carefully inspected
and were included only if fulfilling the quality criteria of LCmodel.
We have to acknowledge some limitations of the study;
unfortunately at the time of the study we were not able to analyze
plasma samples of proline and glutamine of healthy controls.
Future studies with large sample sizes including healthy volunteers,
should elucidate the relationship between plasma levels (of proline,
glutamate, glutamine), cerebral metabolites and the vulnerability
to schizophrenia. We did not determine the size of deleted region
in each 22q11DS patient although the majority of patients have a
typically deleted 3 Mb region. We did not to apply a correction for
multiple comparisons because the possibility of inflating type II
error [58]. Since increased hippocampal glutamate possibly corro-
borates the involvement of glutamate in psychosis [11,41,59] and
converging evidence from animal and human studies propose the
hippocampus as crucial brain area involved in the vulnerability to
schizophrenia [60,61] we chose to avoid a too stringent evaluation.
We were not able to determine tissue contributions to measured
metabolites; the use of unsegmented voxels (i.e., assessment of
metabolite concentrations without addressing the impact of
different tissue included in the voxel of interest) may increase the
standard error of measurement and diminish the power to detect
significant differences. The cubic shape of hippocampal voxel may
have allowed for contamination signals from adjacent regions of
the hippocampus. Moreover, the effect of medication can be a
potentially confounding factor in 1H-MRS studies [62]. In our
study, antipsychotic drugs may have affected metabolites concen-
trations of frontal lobe in 22q11DS SCZ+. In fact, in the DLPFC,
unlike in the hippocampus, we found a significant positive
correlation between dosage of medication and glutamine concen-
tration and a trend towards positive correlation between dosage of
medication and Glx concentration in 22q11DS SCZ+ patients.
This may also indicate that antipsychotics modulates neuronal
metabolism in a regionally specific fashion.
Due to similar chemical components glutamate and glutamine
overlap significantly in the 1H resonance spectrum. The use of
higher field strengths and implemented spectroscopy analysis
technique makes it possible to improve glutamate quantification.
Discrepancies across earlier 1H-MRS studies that proposed to
investigate glutamate in psychosis could have resulted from
differences in brain regions of interest, patient population and
stage of disease or issues of spectroscopy measurements.
In conclusion, our findings suggest vulnerability of the
hippocampus in the psychopathology of 22q11DS SCZ+.
Although the generalizability of the results is restricted by the
relatively small sample size, altered glutamate and myo-inositol
metabolism may partially explain the psychotic symptoms and
cognitive impairments seen in this group of patients. Future 1H-
MRS studies with larger sample sizes including other prefrontal
and temporal brain regions will help to clarify brain metabolism
and integrity in 22q11DS.
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